National Health (IVF/GIFT Program) Special Arrangement Amendment Instrument 2013 (No. 1) (No. PB 44 of 2013) (Cth)
PB 44 of 2013
National Health (IVF/GIFT Program) Special Arrangement Amendment Instrument 2013 (No.1)
National Health Act 1953
I, STEVE DUNLOP, Acting Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Medical Research, make this Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated 30 July 2013
STEVE DUNLOP
A/g Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Divison
Department of Health and Ageing
1 Name of Instrument
(1) This Instrument is the National Health (IVF/GIFT Program)
Special Arrangement Amendment Instrument 2013 (No.1).
(2) This Instrument may also be cited as PB 44 of 2013.
2 Commencement
This Instrument commences on 1 August 2013.
3 Amendment of PB 93 of 2011
(1) Schedule 1 amends the National Health (IVF/GIFT Program) Special Arrangement 2011 (PB 93 of 2011).
Schedule 1 Amendments
Section 4, definition of eligible patient
substitute:
eligible patient means a person who:
(a) is an eligible person within the meaning of the Health Insurance Act 1973;
(b) is receiving treatment:
(i) mentioned in item 13200, 13201, 13202 or 13203 of the general medical services table; and
(ii) for which Medicare benefit is payable; and
(c)satisfies the treatment conditions, if any, mentioned in the column in Schedule 3 headed ‘Treatment Conditions’ for a pharmaceutical benefit with a drug and form mentioned for that treatment condition in Schedule 3.
Schedule 1, entry for Progesterone in the form Pessary 100 mg
substitute:
| Progesterone | Pessary 100 mg | Vaginal | Oripro | ON | D(100) |
Schedule 1, entry for Progesterone in the form Pessary 200 mg
substitute:
| Progesterone | Pessary 200 mg | Vaginal | Oripro | ON | D(100) |
After Schedule 2
Insert:
Schedule 3 Treatment Conditions
(section 4)
| Treatment Condition Number | Treatment Conditions | Listed Drug in Pharmaceutical Benefit | Form |
| 1 | A patient who: (iii) Is undergoing a gonadotrophin releasing hormone antagonist cycle | Corifollitropin Alfa | Solution for injection 100 micrograms in 0.5ml single dose pre-filled syringes |
| 2 | A patient who: (i) Has an antral follicle count of 20 or less; and (ii) Is undergoing a gonadotrophin releasing hormone antagonist cycle | Corifollitropin Alfa | Solution for injection 150 micrograms in 0.5ml single dose pre-filled syringes |
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0